Mission Statement

Afromics is on a mission to ensure that people of African ancestry, both across the African continent and throughout the global diaspora, are equitably represented in genomics, driving inclusive healthcare innovation that benefits Africa and the world.

Headquartered in Cambridge, UK, Afromics is building a next-generation biobank representing 5 million individuals of African ancestry over the next decade. This resource will integrate genomic, clinical, deeply phenotyped, and demographic data to create an unprecedented platform for global research, enabling new insights into disease biology, drug response, and population health.

Crucially, Afromics is committed to ensuring that the benefits of genomics reach participants and communities directly. Every participant will receive a personalised pharmacogenetic report that translates their genomic data into actionable prescribing guidance for pain medications. By using information about an individual’s drug-metabolism genes, these reports help clinicians select safer and more effective treatments, ensuring that participants themselves are the first to benefit.

By harnessing the immense genetic diversity of African and African diaspora populations, Afromics aims to transform the future of precision medicine, enabling more accurate disease diagnosis, improving treatment outcomes, and accelerating the discovery of new drug targets. By placing African communities at the centre of genomic research, Afromics is working towards a future where medical breakthroughs are representative, inclusive, and globally impactful.